Johnson & Johnson will acquire Abiomed through a tender offer valued at $16.6 billion, the two companies announced Tuesday. Abiomed is known for its family of Impella mechanical circulatory support devices, which are used in high-risk percutaneous coronary intervention and acute heart failure. “We are pleased to have reached an agreement that reflects the remarkable value Abiomed created with our revolutionary Impella® heart pump platform and promising pipeline,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer, in a news release announcing the deal. “This transaction partners us with an organization that shares our patients-first mindset and creates immediate value for our patients, customers, employees and shareholders. It will enable us to leverage Johnson & Johnson’s global scale, commercial strength and clinical expertise to accelerate our mission of making heart recovery the global standard of care.” Officials of Johnson & Johnson, the largest and most diversified healthcare products company, said the acquisition will grow and diversify its presence in cardiovascular devices. “The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” said Joaquin Duato, Chief Executive Officer of Johnson & Johnson, in the news release. “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.” Once the acquisition is complete, Abiomed will operate as a standalone business within Johnson & Johnson MedTech, the news release states. The transaction is expected to be complete by March 2023. The announcement comes 1 day after Abiomed announced that its Impella Flex RP Flex with SmartAssist received premarket approval from the U.S. Food and Drug Administration as a safe and effective treatment for acute right heart failure for up to 14 days. Abiomed said the device “will be introduced in the U.S. through a controlled rollout this quarter.” Image of Impella RP Flex courtesy of Abiomed